{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:43:02Z","timestamp":1787006582841,"version":"build-2736575974"},"reference-count":34,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"National Institute on Drug Abuse of the National Institutes of Health","award":["K23DA038720"],"award-info":[{"award-number":["K23DA038720"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background and aims<\/jats:title>\n                    <jats:p>Opioid agonist therapies (OATs) are highly effective treatments for opioid use disorders (OUDs), especially for pregnant women; thus, improving access to OAT is an urgent public policy goal. Our objective was to determine if insurance and pregnancy status were barriers to obtaining access to OAT in 4 Appalachian states disproportionately impacted by the opioid epidemic.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between April and May 2017, we conducted phone surveys of OAT providers, opioid treatment programs (OTPs), and outpatient buprenorphine providers, in Kentucky, North Carolina, Tennessee, and West Virginia. Survey response rates were 59%. Logistic models for dichotomous outcomes (e.g., patient acceptance) and negative binomial models were created for count variables (e.g., wait time), overall and for pregnant women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The majority of OAT providers were accepting new patients; however, providers were less likely to treat pregnant women (91% vs. 75%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.01). OTPs were more likely to accept new patients than waivered buprenorphine providers (97% vs. 83%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u2009.01); rates of accepting pregnant patients were lower in both (91% and 53%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.01). OTPs and buprenorphine providers accepted cash payments for services at high rates (OTP: 100%; buprenorphine: 89.4%;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u2009.01); Medicaid and private insurance were accepted at lower rates. In adjusted models, providers were less likely to accept pregnant women if they took any insurance (adjusted odds ratio [aOR]\u2009=\u20090.15, 95% confidence interval [CI]: 0.03\u20130.68) or were a buprenorphine provider (aOR\u2009=\u20090.09, 95% CI: 0.02\u20130.37).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We found that OAT providers frequently did not accept any insurance and frequently did not treat pregnant women in an area of the country disproportionately affected by the opioid epidemic. Policymakers could prioritize improvements in provider training (e.g., training of obstetricians to become buprenorphine prescribers) as a means to enhance access to pregnant women or enhancing reimbursement rates as a means of improving insurance acceptance for OAT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1080\/08897077.2018.1488336","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T12:32:57Z","timestamp":1530102777000},"page":"356-362","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":70,"title":["Barriers to Accessing Treatment for Pregnant Women with Opioid Use Disorder in Appalachian States"],"prefix":"10.1177","volume":"40","author":[{"given":"Stephen W.","family":"Patrick","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Vanderbilt University, Nashville, Tennessee, USA;"},{"name":"Mildred Stahlman Division of Neonatology, Vanderbilt University, Nashville, Tennessee, USA;"},{"name":"Department of Pharmacology, Vanderbilt Center for Health Services Research, Nashville, Tennessee, USA;"},{"name":"Department of Health Policy, Vanderbilt University, Nashville, Tennessee, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda B.","family":"Buntin","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University, Nashville, Tennessee, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Vanderbilt University, Nashville, Tennessee, USA;"},{"name":"Department of Pharmacology, Vanderbilt University, Nashville, Tennessee, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa A.","family":"Scott","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vanderbilt University, Nashville, Tennessee, USA;"},{"name":"Mildred Stahlman Division of Neonatology, Vanderbilt University, Nashville, Tennessee, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Dupont","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Richards","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University, Nashville, Tennessee, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William O.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Vanderbilt University, Nashville, Tennessee, USA;"},{"name":"Department of Health Policy, Vanderbilt University, Nashville, Tennessee, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,7,1]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/M17-0865"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2013.05.017"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000000208"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.3951"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2016.3750"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000001446"},{"key":"e_1_3_4_8_2","unstructured":"Maryland Maternal Mortality Review 2016 Annual Report. Annapolis Maryland: Maryland Department of Health and Mental Hygiene Prevention and Health Promotion Administration 2016."},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6531a2"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1500439"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/jp.2015.36"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e318256496e"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201300235"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.10.1303"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2005.03.072"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2011.01.008"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03700.x"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11524-010-9451-7"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2012.301049"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.58.5.681"},{"key":"e_1_3_4_21_2","volume-title":"Opioid Addiction: Laws, Regulations and Other Factors can Affect Medication-Assisted Treatment Access","author":"Curda EH","year":"2016","unstructured":"Curda EH. Opioid Addiction: Laws, Regulations and Other Factors can Affect Medication-Assisted Treatment Access. Washington, D.C.: Government Accountability Office; 2016."},{"key":"e_1_3_4_22_2","volume-title":"Final Report","author":"Crisis TPsCoCDAatO","year":"2017","unstructured":"Crisis TPsCoCDAatO. Final Report. Washington, D.C.: Executive Office of the President, The White House; 2017."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.12178"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.07.007"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6626a4"},{"key":"e_1_3_4_26_2","unstructured":"Number and age-adjusted rates of drug overdose deaths by state US 2015. 2017; https:\/\/www.cdc.gov\/drugoverdose\/data\/statedeaths.html.AccessedJune16 2017."},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6450a3"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6618a3"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/1178221817699247"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-3299"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002235"},{"key":"e_1_3_4_32_2","unstructured":"Prevention CfDCa. Prescription Opioid Overdose Data. 2016; http:\/\/www.cdc.gov\/drugoverdose\/data\/overdose.html.AccessedDecember5 2016."},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000092"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005359"},{"key":"e_1_3_4_35_2","unstructured":"Substance Use During Pregnancy. 2018; https:\/\/www.guttmacher.org\/state-policy\/explore\/substance-use-during-pregnancy. Accessed March 8 2018."}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2018.1488336","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/08897077.2018.1488336","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2018.1488336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:26:35Z","timestamp":1780489595000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/08897077.2018.1488336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1080\/08897077.2018.1488336"],"URL":"https:\/\/doi.org\/10.1080\/08897077.2018.1488336","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}